Share: Facebook Twitter LinkedIn
Activity Provided By:

Purdue University College of Pharmacy

What’s My (Next) Line? Treating Relapsed/Refractory Multiple Myeloma When Three Prior Treatment Lines Fail

Access Activity

Overview / Abstract:

Although outcomes for patients with multiple myeloma (MM) have improved with targeted agents and combination therapies, most MM patients inevitably relapse. Furthermore, the duration and quality of response to treatment deteriorates following each subsequent line of therapy, and the risk of another relapse rises. The emergence of B-cell maturation antigen (BCMA)-targeting antibody-drug conjugates, bispecific antibodies, CAR T-cell therapy, and novel small-molecule agents has offered innovative treatment options for patients with MM that has relapsed or become refractory (RRMM) to several lines of therapy.

This activity has been developed to present and discuss current recommended strategies for individualizing treatment plans for patients with RRMM by incorporating the most up-to-date clinical evidence on sequencing small molecule"based therapies and BCMA-targeted therapies that achieve durable remission while minimizing toxicity.

Expiration

Sep 30, 2023

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Online

Credits / Hours

1.0

Accreditation

ACCME

Presenters / Authors / Faculty

Amrita Y. Krishnan, MD
Director of Judy and Bernard Briskin Multiple Myeloma Center
Professor of Hematology/Hematopoietic Cell Transplantation
City of Hope Cancer Center
Duarte, California

Saad Z. Usmani, MD, MBA, FACP
Chief of Myeloma Service
Member
Memorial Sloan Kettering Cancer Center
Attending Physician, Myeloma, Cellular Therapy and Adult BMT Services
New York, New York

Activity Specialities / Related Topics

Hematology, Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

Support for this activity has been provided through educational grants from GSK and Pfizer.

Keywords / Search Terms

RedMedEd RedMedEd, B-cell maturation antigen, BCMA, belantamab mafodotin, belmaf, bispecific antibodies, bortezomib, carfilzomib, CAR T-cell therapy, cilta-cel, ciltacabtagene autoleucel, CRS, cytokine release syndrome, daratumumab, dexamethasone, elranatamab, iberdomide, idecabtagene vicleucel, immunotherapy, lenalidomide, pomalidomide, relapsed/refractory multiple myeloma, selinexor, talquetamab, teclistamab, tocilizumab, venetoclax Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map